Medindia LOGIN REGISTER
Medindia

New Biomarker for Arrhythmogenic Cardiomyopathy Identified

by Colleen Fleiss on Feb 13 2020 12:43 AM

High levels of ketone bodies in the plasma of arrhythmogenic cardiomyopathy (AC) patients could serve as a reliable predictor of AC progression, said new study.

New Biomarker for Arrhythmogenic Cardiomyopathy Identified
A new metabolic biomarker that tracks the progression of arrhythmogenic cardiomyopathy (AC) has been discovered by scientists. AC is an inherited heart condition that can kill swiftly and without warning.
Even in patients with a family history of AC, sudden cardiac death is often the first detectable symptom of the disease. There are currently no clinical assessments specific for AC, and patients can remain outwardly healthy for up to 40 years.

Now, building on prior work that indicated metabolic abnormalities in the heart muscle of AC patients, Jiang-Ping Song and colleagues have found that high levels of ketone bodies in the plasma of AC patients could serve as a reliable predictor of AC progression.

The researchers compared heart tissue from a cohort of 13 AC patients with heart tissue from 13 healthy donors and found increased expression of enzymes involved in ketone metabolism in the AC patients' hearts. They also compared plasma samples from AC patients, healthy volunteers, and patients diagnosed with other cardiopulmonary diseases, and found elevated levels of ketone bodies - especially β-hydroxybutyrate - in the AC patient samples.

In a final validation step, the researchers compared plasma from a cohort of 65 AC patients, 94 of their relatives, and 62 healthy volunteers, and found elevated β-hydroxybutyrate levels in the AC patients and some of their relatives. The findings suggest that β-hydroxybutyrate could serve as a reliable predictor of AC progression in those suspected to be at risk of the disease.

Source-Eurekalert


Advertisement

Home

Consult

e-Book

Articles

News

Calculators

Drugs

Directories

Education